journal
Journals Lung Cancer : Journal of the I...

Lung Cancer : Journal of the International Association for the Study of Lung Cancer

https://read.qxmd.com/read/38359742/hla-i-levels-correlate-with-survival-outcomes-in-response-to-immune-checkpoint-inhibitors-in-non-small-cell-lung-cancer
#21
JOURNAL ARTICLE
Maria Saigí, Jose L Mate, Enric Carcereny, Anna Martínez-Cardús, Anna Esteve, Felipe Andreo, Carmen Centeno, Marc Cucurull, Ricard Mesia, Eva Pros, Montse Sanchez-Cespedes
OBJECTIVES: Immune checkpoint inhibitors (ICIs) have provided a breakthrough in the treatment of non-small cell lung cancer (NSCLC) patients, but only some patients benefit substantively. Identifying definitive predictive biomarkers could overcome this limitation. MATERIALS AND METHODS: We selected 146 metastatic NSCLC patients treated with anti-PD-(L)1. Immunohistochemistry of HLA-I, PD-L1 and CD73 was performed in 122 tumor biopsies at diagnosis. The association with patients, tumor parameters, and the predictive value to ICI treatment were determined...
February 8, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38324922/clinical-application-of-the-lung-cancer-compact-panel-tm-using-various-types-of-cytological-specimens-in-patients-with-lung-cancer
#22
JOURNAL ARTICLE
Kei Kunimasa, Motohiro Tamiya, Takako Inoue, Takahisa Kawamura, Akito Miyazaki, Yoshiki Kojitani, Keiichiro Honma, Kazumi Nishino
BACKGROUND: The Lung Cancer Compact PanelTM (compact panel) is a gene panel that can detect driver alterations with high sensitivity in liquid samples, including tumor cells. This study examined the ability of a compact panel to detect genetic mutations in liquid specimens used in clinical practice. METHODS: Three cohorts, bronchoscopic biopsy forceps washing (washing cohort), pleural effusion (pleural cohort), and spinal fluid (spinal cohort), were analyzed using the compact panel...
February 3, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38301600/clinical-management-of-nut-carcinoma-nc-in-germany-analysis-of-survival-therapy-response-tumor-markers-and-tumor-genome-sequencing-in-35-adult-patients
#23
JOURNAL ARTICLE
Linus D Kloker, Mirjana Sidiras, Tim Flaadt, Ines B Brecht, Christoph K W Deinzer, Thorben Groß, Katrin Benzler, Lars Zender, Ulrich M Lauer
NUT carcinomas (NC) are very rare and highly aggressive tumors, molecularly defined by an aberrant gene fusion involving the NUTM1 gene. NCs preferentially arise intrathoracically or in the head and neck region, having a highly adverse prognosis with almost no long-term survivors. Here, we report on a cohort of 35 adult NC patients who were evaluated at University Hospital Tuebingen in an eight year time span, i.e. between 2016 and 2023. Primary objectives were overall survival (OS) and influence of primary tumor locations, fusion gene types and staging on OS...
January 29, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38295631/prognostic-value-of-the-scottish-inflammatory-prognostic-score-in-patients-with-nsclc-expressing-pd-l1%C3%A2-%C3%A2-%C3%A2-50%C3%A2-progressing-on-first-line-pembrolizumab
#24
JOURNAL ARTICLE
Mark Stares, Emma Doyle, Sally Chapple, George Raynes, James MacDonald, Colin Barrie, Barry Laird, Melanie MacKean, Iain Philips
BACKGROUND: Most patients with advanced non-small cell lung cancer (NSCLC) treated with first-line pembrolizumab monotherapy will experience progressive disease (PD). Only a minority will go on to receive subsequent systemic anticancer therapy for which outcomes are guarded. We investigated the prognostic significance of biomarkers of systemic inflammation following failure of first-line pembrolizumab for NSCLC to aid subsequent management decisions. METHODS: Patients with radiological and/or clinical evidence of PD on first-line pembrolizumab for advanced NSCLC at a regional Scottish cancer centre were identified...
January 29, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38335691/insensitivity-of-oncogenic-egfr-r776l-mutation-to-egfr-inhibitors-in-lung-cancer
#25
Yun Wang, Chen Hu, Hongwei Yu, Jie Hu, Zhiwei Zhou, Ning Fu, Xiang Huang, Fanhao Kong, Wenchao Wang, Jing Liu
Non-small cell lung cancers (NSCLC) account for 85 % of total lung cancers. Mutation in EGFRdrives the progress of NSCLSs with high mortality rate. Besides the common mutations in EGFR, which together comprise of 85 % of all EGFR mutations and respond to the targeted therapy of EGFR tyrosine kinase inhibitors (TKIs), many other low-frequency mutations of EGFR are existed in patients. The oncogenic roles and sensitivity of these mutations to EGFR TKIs are not fully understood yet. Here we described two cases of lung adenocarcinoma patients harboring EGFR R776L missense mutation, showed PD and SD after treatment with third-generation EGFR inhibitor, Almonertinib...
January 28, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38320371/incorporation-of-the-lepidic-component-as-an-additional-pathological-t-descriptor-for-non-small-cell-lung-cancer-data-from-3335-cases-of-lung-adenocarcinoma
#26
JOURNAL ARTICLE
Shenghao Huang, Mengmeng Zhao, Shenghui Li, Tao Chen, Yifan Zhong, Jiajun Deng, Long Xu, Junqi Wu, Xiaofeng Xie, Chunyan Wu, Likun Hou, Yunlang She, Hui Zheng, Chang Chen
OBJECTIVES: The Lepidic Component (LP) identifies a subgroup with an excellent prognosis for lung adenocarcinoma (LUAD). Our research aimed to propose an improved pathological T (pT) stage for LUAD based on LP. MATERIALS AND METHODS: Totally, 3335 surgical patients with pathological stage I LUAD were incorporated. Factors affecting survival were investigated by analyzing recurrence-free survival (RFS) and overall survival (OS) using the Kaplan-Meier method and Cox regression analyses...
January 26, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38301599/resolving-asbestos-and-ultrafine-particulate-definitions-with-carcinogenicity
#27
JOURNAL ARTICLE
Sean M Fitzgerald
As asbestos fibers and other fine particles have been studied extensively to correlate physical and chemical properties with their potential for negative human health impact on inhalation, there remains no concise definitions for the individual particle types nor collective considerations of combined variabilities. Extensive studies relating negative health to asbestos morphology, chemistry, surface effects, and biodurability form general qualitative bins of what is more likely causative or less, but do not provide enough information to quantitatively dismiss particles with parameters outside any given range...
January 26, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38306885/international-reproducibility-study-of-thymic-epithelial-tumors-staging-pt-stage-is-an-issue-proposals-for-improvement-a-rythmic-itmig-study
#28
JOURNAL ARTICLE
Thierry J Molina, Anja C Roden, Malgorzata Szolkowska, Shigeki Shimizu, Andre L Moreira, Lara Chalabreysse, Benjamin Besse, Vincent de Montpréville, Edith M Marom, Frank Detterbeck, Nicolas Girard, Andrew G Nicholson, Alexander Marx
INTRODUCTION: Pathologists are staging thymic epithelial tumors (TET) according to the 8th UICC/AJCC TNM system. Within the French RYTHMIC network, dedicated to TET, agreement on pathologic tumor stage (pT) among the pathology panelists was difficult. The aim of our study was to determine the interobserver reproducibility of pT at an international level, to explore the source of discrepancies and potential interventions to address these. METHODS: An international panel of pathologists was recruited through the International Thymic Malignancy Interest Group (ITMIG)...
January 24, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38280290/pulmonary-blastoma-is-successfully-treated-with-immunotherapy-and-targeted-therapy
#29
REVIEW
Yicong Chen, Huijiao Chen, Ruixuan Yu, Xiaoxiao Zeng, Dong Tian, Qiang Pu, Yongmei Liu
Pulmonary blastomas (PB) are an extremely rare type of lung cancer. Currently, no standard treatment exists for PB. Immunotherapy with checkpoint inhibitors and anti-angiogenesis treatments has been an effective method for lung cancer; however, studies on PB treatment are lacking. Herein, we present a case report of successful conversion therapy with immunotherapy and targeted therapy for PB. After receiving treatment with a PD-1 inhibitor (penpulimab) and a multi-target tyrosine kinase inhibitor (anlotinib) treatment, the patient showed an impressive response and underwent a successful operation...
January 24, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38271919/strengths-and-challenges-in-current-lung-cancer-care-timeliness-and-diagnostic-procedures-in-six-dutch-hospitals
#30
JOURNAL ARTICLE
Sylvia A A M Genet, Esther Visser, Maggy Youssef-El Soud, Huub N A Belderbos, Gerben Stege, Marleen E A de Saegher, Susan C van 't Westeinde, Luc Brunsveld, Maarten A C Broeren, Daan van de Kerkhof, Federica Eduati, Ben E E M van den Borne, Volkher Scharnhorst
OBJECTIVES: Timely diagnosis of lung cancer (LC) is crucial to achieve optimal patient care and outcome. Moreover, the number of procedures required to obtain a definitive diagnosis can have a large influence on the life expectancy of a patient. Here, adherence with existing Dutch guidelines for timeliness and type and number of invasive and imaging procedures was assessed. MATERIALS AND METHODS: 1096 patients with suspected LC were enrolled in this multicenter prospective study (NL9146)...
January 22, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38266613/effectiveness-of-high-dose-third-generation-egfr-tyrosine-kinase-inhibitors-in-treating-egfr-mutated-non-small-cell-lung-cancer-patients-with-leptomeningeal-metastasis
#31
JOURNAL ARTICLE
Haicheng Wu, Qian Zhang, Wanchen Zhai, Yunfei Chen, Yehao Yang, Mingning Xie, Zhiyu Huang, Yanjun Xu, Hui Li, Lei Gong, Sizhe Yu, Yun Fan, Kaiyan Chen
BACKGROUND: Leptomeningeal metastasis (LM) is associated with an extremely poor prognosis in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). The third-generation EGFR-tyrosine kinase inhibitors (TKIs), currently the preferred drug of choice, have significantly improved treatment outcomes in these patients. However, the optimal dose of third-generation EGFR-TKIs for clinical use remains undetermined in NSCLC patients with LM. METHODS: We retrospectively analyzed the clinical characteristics and treatment outcomes of 105 patients with EGFR-mutated NSCLC and cytologically confirmed LM who had received third-generation EGFR-TKI treatment after LM diagnosis...
January 20, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38341295/a-multidisciplinary-review-of-several-aspects-of-asbestos-related-lung-cancer-arlc
#32
EDITORIAL
Nico van Zandwijk, Arthur L Frank
No abstract text is available yet for this article.
January 17, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38354535/canakinumab-in-combination-with-docetaxel-compared-with-docetaxel-alone-for-the-treatment-of-advanced-non-small-cell-lung-cancer-following-platinum-based-doublet-chemotherapy-and-immunotherapy-canopy-2-a-multicenter-randomized-double-blind-phase-3-trial
#33
JOURNAL ARTICLE
Luis Paz-Ares, Yasushi Goto, Darren Wan-Teck Lim, Balazs Halmos, Byoung Chul Cho, Manuel Cobo, José Luis González Larriba, Caicun Zhou, Ingel Demedts, Akin Atmaca, Sofia Baka, Bijoyesh Mookerjee, Socorro Portella, Zewen Zhu, Jincheng Wu, David Demanse, Bharani Dharan, Martin Reck
OBJECTIVES: Canakinumab, an interleukin-1 beta inhibitor, previously showed reduced lung cancer incidence and mortality (CANTOS). Here, we compare the efficacy/safety of canakinumab versus placebo in patients with advanced non-small cell lung cancer (NSCLC) who had progressed after platinum-based doublet chemotherapy (PDC) and immunotherapy. MATERIALS AND METHODS: CANOPY-2, a randomized, double-blind, phase 3 trial, enrolled adult patients with stage IIIB/IV NSCLC, without EGFR or ALK alterations, who had received one prior PDC regimen and one prior programmed death-1/programmed death-ligand 1 inhibitor and experienced subsequent disease progression...
January 16, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38306886/thoracic-smarca4-deficient-undifferentiated-tumor-a-clinicopathological-and-prognostic-analysis-of-35-cases-and-immunotherapy-efficacy
#34
JOURNAL ARTICLE
Ping Zhou, Yiyun Fu, Yuan Tang, Lili Jiang, Weiya Wang
BACKGROUND: Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a recently recognized distinct clinicopathological entity according to the fifth edition of the 2021 World Health Organization Classification (WHO) for thoracic tumors. Thoracic SMARCA4-UTs are diagnostically challenging to diagnose, especially on small biopsies. METHODS: We identified 35 thoracic SMARCA4-UTs from the Department of Pathology of West China Hospital, Sichuan University, between January 2017 and December 2022...
January 13, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38219288/real-world-outcomes-associated-with-afatinib-use-in-patients-with-solid-tumors-harboring-nrg1-gene-fusions
#35
JOURNAL ARTICLE
Stephen V Liu, Claas Frohn, Lori Minasi, Kristie Fernamberg, Andrew J Klink, Ajeet Gajra, Kristin M Zimmerman Savill, Sushma Jonna
OBJECTIVES: Neuregulin-1 (NRG1) fusions may drive oncogenesis via constitutive activation of ErbB signaling. Hence, NRG1 fusion-driven tumors may be susceptible to ErbB-targeted therapy. Afatinib (irreversible pan-ErbB inhibitor) has demonstrated activity in individual patients with NRG1 fusion-positive solid tumors. This study collected real-world data on demographics, clinical characteristics, and clinical outcomes in this patient population. MATERIALS AND METHODS: In this retrospective, multicenter, non-comparative cohort study, physicians in the US-based Cardinal Health Oncology Provider Extended Network collected data from medical records of patients with NRG1 fusion-positive solid tumors who received afatinib (afatinib cohort) or other systemic therapies (non-afatinib cohort) in any therapy line...
January 5, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38224653/myeloprotection-with-trilaciclib-in-chinese-patients-with-extensive-stage-small-cell-lung-cancer-receiving-chemotherapy-results-from-a-randomized-double-blind-placebo-controlled-phase-iii-study-traces
#36
JOURNAL ARTICLE
Ying Cheng, Lin Wu, Dingzhi Huang, QiMing Wang, Yun Fan, XiQin Zhang, HuiJie Fan, WenXiu Yao, BaoGang Liu, GuoHua Yu, YueYin Pan, Fei Xu, ZhiYong He, XiaoRong Dong, Rui Ma, XuHong Min, XiaoSong Ge, Hualin Chen, Qun Liu, YanPing Hu, Ying Liu, Chen Yang, Yang Yang, Xiucui Li, Li Zhou
INTRODUCTION: Trilaciclib is a transient cyclin-dependent kinase 4/6 inhibitor that decreases the incidence of chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer (ES-SCLC). TRACES study was designed to assess the safety, efficacy and pharmacokinetics (PK) of trilaciclib before chemotherapy in Chinese patients with ES-SCLC. METHODS: The study included an open-label safety run-in part (Part 1) and double-blinded, placebo-controlled part (Part 2) where patients received trilaciclib or placebo before chemotherapy...
December 31, 2023: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38160082/corrigendum-to-osimertinib-as-first-line-treatment-for-elderly-patients-with-advanced-egfr-mutation-positive-non-small-cell-lung-cancer-in-a-real-world-setting-osi-fact-ep-lung-cancer-186-2023-107426
#37
Yoshihiko Sakata, Go Saito, Shinya Sakata, Yuko Oya, Motohiro Tamiya, Hidekazu Suzuki, Ryota Shibaki, Asuka Okada, Toshihide Yokoyama, Hirotaka Matsumoto, Taiichiro Otsuki, Yuki Sato, Uchida Junji, Yoko Tsukita, Megumi Inaba, Hideki Ikeda, Daisuke Arai, Hirotaka Maruyama, Satoshi Hara, Shinsuke Tsumura, Jun Morinaga, Takuro Sakagami
No abstract text is available yet for this article.
December 29, 2023: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38159439/real-world-comprehensive-genomic-profiling-data-for-diagnostic-clarity-in-pulmonary-large-cell-neuroendocrine-carcinoma
#38
JOURNAL ARTICLE
Laura Burns, Hanna Tukachinsky, Kira Raskina, Richard S P Huang, Alexa B Schrock, Jacob Sands, Matthew H Kulke, Geoffrey R Oxnard, Umit Tapan
BACKGROUND: Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is an uncommon subtype of lung cancer believed to represent a spectrum of tumors sharing characteristics of both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Other groups have proposed genomic LCNEC subtypes, including small cell-like, non-small cell-like, and carcinoid-like subtypes. The primary goal of this study was to better define the NSCLC-like subtype with comprehensive genomic profiling (CGP)...
December 29, 2023: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38184958/sfxn1-as-a-potential-diagnostic-and-prognostic-biomarker-of-luad-is-associated-with-18-f-fdg-metabolic-parameters
#39
JOURNAL ARTICLE
Yao-Hua Zhang, Xu-Sheng Liu, Yan Gao, Ling-Ling Yuan, Zhong-Min Huang, Yu Zhang, Zi-Yue Liu, Yi Yang, Xiao-Yu Liu, Chang-Bin Ke, Zhi-Jun Pei
BACKGROUND: Sideroflexin 1 (SFXN1) has been discovered as a novel tumor marker for lung adenocarcinoma, but data on its importance in the development of lung adenocarcinoma is still limited. This study evaluated the correlation between SFXN1 and parameters related to 18 F-flurodeoxyglucose (18 F-FDG) positron emission tomography/computed tomography (PET/CT), and further explored the role of SFXN1 in the value-added and glycolytic processes of LUAD. METHOD: The expression and prognostic value of SFXN1 mRNA in LUAD were analyzed using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) data base...
December 27, 2023: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38176297/colony-stimulating-factor-1-csf-1-signalling-is-predictive-of-response-to-immune-checkpoint-inhibitors-in-advanced-non-small-cell-lung-cancer
#40
JOURNAL ARTICLE
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, Claude Capron, Florence Parent, Andrei Seferian, Catherine Guettier, Jean-François Emile, Etienne Giroux Leprieur
The identification of biomarkers related to treatment in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) represents a significant challenge. The aim of this study was to determine the predictive value of macrophage-related markers assessed in plasma and tissue samples of patients with NSCLC undergoing ICI treatment. This bicentric study included a prospective cohort of 88 patients with advanced NSCLC who received first-line therapy with ICI (either as monotherapy or in combination with chemotherapy) or chemotherapy alone (CT)...
December 24, 2023: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.